Discover how antiviral defences affect viral vector manufacturing in our upcoming webinar.
TORONTO, Ontario (PRWEB)
May 24, 2023
Viral-based gene therapies are emerging as a promising solution for the treatment of complex and rare diseases. However, the demand for adeno-associated viruses (AAVs) as a delivery vehicle for gene therapy has unsurprisingly led to a manufacturing bottleneck. While the search for solutions is ongoing, recent evidence has revealed that antiviral defenses in cellular immunity present in manufacturing cell lines are a potential barrier that is frequently overlooked.
In an upcoming webinar hosted by Xtalks, we will explore the impact of antiviral defenses on viral vector production systems, why unraveling viral vector quality metrics beyond raw titers is essential, and how increased functional viral yield can be achieved.
Experts from Virica Biotech, including CEO Dr. Jean-Simon Diallo, VP Scientific Operations Dr. Jondavid de Jong, and Technical Lead Benjamin McLeod (Moderator), will discuss a simple media additive that could help tackle viral vector scalar challenges and share their vision for the future of viral vector manufacturing in the biotech industry.
The live webinar will take place on Tuesday, June 13th, 2023, at 11 am EDT (4 pm BST/UK). Follow the link provided to register for the webinar and discover how antiviral defenses impact viral vector manufacturing.
ABOUT VIRICA BIOTECH
As the first company to develop and commercialize Viral Sensitizers (VSE™), Virica Biotech has provided a solution to the viral vector manufacturing challenge of antiviral defenses. It has done so by producing patented small molecules, including both known drugs and novel synthetic compounds, that transiently attenuate antiviral pathways in cells and may increase both virus production and the therapeutic efficacy of viral medicines.
Virica’s high-throughput virology methods have so far identified over 100+ VSEs, leading to its evolution beyond research conducted by Virica’s Scientific Founder and CEO, Dr. Jean-Simon Diallo, who remains a world-recognized leader in oncolytic viral therapies, at the Ottawa Hospital Research Institute (OHRI).
Virica Biotech’s services include formulation development with off-the-shelf or custom solutions as well as in-house evaluation or at-site evaluation support.
Learn more about Virica Biotech and visit them on LinkedIn using the link provided.
ABOUT XTALKS
Xtalks is a leading provider of educational webinars and quality content for the global life science, food and medical device communities. Every year, thousands of industry practitioners including life science, food and medical device companies, private & academic research institutions, healthcare centers, among others, turn to Xtalks for access to accurate industry developments, trends, and regulations. Xtalks webinars provide perspectives on key issues from top industry thought leaders and service providers, helping life science professionals stay current with the industry.
For more information about Xtalks, including hosting webinars, visit xtalks.com.
For more information or to register for this particular event, follow the link provided.
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com
Please share the article via social media or email with the links available.
